Keywords: سندرم آزاد سازی سیتوکین; Biotherapeutics; Gene and cell therapy; Pharmacokinetics; Non-clinical safety; Immunogenicity; Cross-reactive species; ATMP; advanced therapy medicinal products; CAR; chimeric antigen receptor; CD; cluster of differentiation; CMC; chemistry manufacturing
مقالات ISI سندرم آزاد سازی سیتوکین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سندرم آزاد سازی سیتوکین; Cytokine release syndrome; CRS; Immunotoxicity; Cytokine release assay; Anti-CD28; Alemtuzumab; OKT3;
Keywords: سندرم آزاد سازی سیتوکین; Infections; Cancer; Neutropenic fever; Hematopoietic stem cell transplant; Cytokine release syndrome; Emergency department;
Keywords: سندرم آزاد سازی سیتوکین; Haploidentical; Post-transplant cyclophosphamide; Cytokine release syndrome;
Keywords: سندرم آزاد سازی سیتوکین; hematopoietic stem cell transplantation; cellular immunotherapy; chimeric antigen receptor T cells; acute complications; neutropenic fever; immunosuppression; graft-versus-host disease; engraftment syndrome; idiopathic pneumonitis syndrome; diffuse alveol
Keywords: سندرم آزاد سازی سیتوکین; Acute lymphoblastic leukemia; ALL; Blinatumomab; CAR; Chimeric antigen receptor; CRS; Cytokine release syndrome; IL-6; Tocilizumab;
Keywords: سندرم آزاد سازی سیتوکین; BBB; blood brain barrier; CAR; chimeric antigen receptor; CNS; central nervous system; CRS; cytokine release syndrome; EGFR; epidermal growth factor receptor; EGFRvIII; variant 3 of epidermal growth factor receptor; epha2; erythropoietin producing hepatoc
Keywords: سندرم آزاد سازی سیتوکین; AML; acute myeloid leukemia; ANC; absolute neutrophil count; CNS; central nervous system; CRS; cytokine release syndrome; CT; computed tomography; IV; intravenous; MRI; magnetic resonance imaging; MSCC; malignant spinal cord compression; PTH; parathyroid
Keywords: سندرم آزاد سازی سیتوکین; ADA; anti-drug antibody; ADCC; antibody-dependent cell cytotoxicity; ADCP; antibody-dependent cell phagocytosis; BiTE; bi-specific T cell engagers; CDC; complement-dependent cytotoxicity; CRA; cytokine release assays; CRS; cytokine release syndrome; DC; d
Keywords: سندرم آزاد سازی سیتوکین; Cytokine release assay; Cytokine release syndrome; Pro-inflammatory cytokines;
Keywords: سندرم آزاد سازی سیتوکین; Cytokine Release Syndrome; Machine learning; Monoclonal antibodies;
Keywords: سندرم آزاد سازی سیتوکین; B2M; beta 2 microglobulin; CAR; cyclophophamide, alvocidib, rituximab; CDK; cyclin-dependent kinase; CLL; chronic lymphocytic leukemia; CR; complete response; CRS; cytokine release syndrome; DLT; dose limiting toxicity; ECOG; Eastern Cooperative Oncology
Keywords: سندرم آزاد سازی سیتوکین; Bispecific T-cell engager; Cytokine release syndrome; Neurotoxicity; Hematopoietic stem cell transplant; Immunotherapy
Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Keywords: سندرم آزاد سازی سیتوکین; Chimeric antigen receptor T cells; CART; Immunotherapy; Adoptive T cell therapy; Adoptive immunotherapy; Hematopoietic stem cell transplantation; Cytokine release syndrome; Neurologic Toxicity;
Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog
Keywords: سندرم آزاد سازی سیتوکین; Cytokine release syndrome; In vitro; TGN1412; Antibody preparation; Screening;
Bispecific antibodies in haematological malignancies
Keywords: سندرم آزاد سازی سیتوکین; Bispecific antibodies; Bispecific t-cell engager; Blinatumomab; Cytokine release syndrome; Neurotoxicity; Acute lymphoblastic leukemia; Non-hodgkin lymphoma;
Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Keywords: سندرم آزاد سازی سیتوکین; Chimeric antigen receptor T cells; CART; Immunotherapy; Adoptive T cell therapy; Adoptive immunotherapy; Hematopoietic stem cell transplantation; Cytokine release syndrome; Neurologic Toxicity;
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Keywords: سندرم آزاد سازی سیتوکین; CRS; cytokine release syndrome; CTL; cytotoxic T lymphocyte; EC50; half maximal effective concentration; Fc; fragment crystallizable; ICI; immune checkpoint inhibitor; pMHC; peptide-major histocompatibility complex; scFv; single chain variable fragment; T
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center
Keywords: سندرم آزاد سازی سیتوکین; CAR T cells; Cellular therapy; Chimeric antigen receptor; Cytokine release syndrome; Diffuse large B cell lymphoma; Acute lymphoblastic leukemia;
Bispecific antibodies for cancer therapy: A review
Keywords: سندرم آزاد سازی سیتوکین; ADCC; antibody-dependent cell-mediated cytotoxicity; AE; adverse events; ALL; acute lymphoblastic leukemia; ALP; alkaline phosphatase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; B-ALL; B-cell acute lymphoblastic leukemia; BiTES; Bi-sp
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
Keywords: سندرم آزاد سازی سیتوکین; NK cell; natural killer cell; IFN-γ; interferon-γ; IL; interleukin; TNF-α; tumor necrosis factor-α; CCL; C-C motif ligand; GM-CSF; granulocyte-macrophage colony-stimulating factor; ADCC; antibody dependent cell-mediated cytotoxicity; TRAIL; TNF-relate
The what, when and how of CAR T cell therapy for ALL
Keywords: سندرم آزاد سازی سیتوکین; Acute lymphoblastic leukemia; Chimeric antigen receptor T cells; Cytokine release syndrome;
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Keywords: سندرم آزاد سازی سیتوکین; CD3 bispecific; MABEL; First-in-human dose; Oncology drug development; FIH; first-in-human; CRA; cytokine release assay; CRS; cytokine release syndrome; GLP; good laboratory practice; HHD; highest human dose; HNSTD; highest non-severely toxic dose; IB; In
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function
Keywords: سندرم آزاد سازی سیتوکین; chimeric antigen receptor; cytokine release syndrome; interleukin 6;
Chimeric antigen receptor T-cells for B-cell malignancies
Keywords: سندرم آزاد سازی سیتوکین; ALL; acute lymphoblastic leukemia; B-ALL; B-cell acute lymphoblastic leukemia; CAR-T; chimeric antigen receptor T-cell; CAR; chimeric antigen receptor; CD; cluster of differentiation; CHOP; Children's Hospital of Philadelphia; CLL; chronic lymphocytic leu
Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy
Keywords: سندرم آزاد سازی سیتوکین; aAPC; artificial antigen-presenting cells; αGalCer; α-galactosylceramide; ACT; adoptive cell transfer; ADCC; antibody-dependent cell-mediated cytotoxicity; ALL; Acute Lymphoblastic Leukemia; AML; acute lymphoid leukemia; CAR; chimeric antigen receptor;
Development of CAR T cells designed to improve antitumor efficacy and safety
Keywords: سندرم آزاد سازی سیتوکین; 28z; CD28 + CD3ζ; 4-1BBL; 4-1BB ligand; B-ALL; B cell acute lymphatic leukemia; BBz; 4-1BB + CD3ζ; CAR; chimeric antigen receptor; CD40L; CD40 ligand; CRS; cytokine release syndrome; CTLA-4; cytotoxic T-lymphocyte associated protein 4; DCs; dendriti
Blinatumomab provoked fatal heart failure
Keywords: سندرم آزاد سازی سیتوکین; Cytokine release syndrome; Tumor lysis syndrome; Fatal cardiac failure; Blinatumomab; Cardiac contractility suppression;
An FDA oncology analysis of immune activating products and first-in-human dose selection
Keywords: سندرم آزاد سازی سیتوکین; MABEL; Immune oncology; First-in-human dose; ADCC; antibody-dependent cellular cytotoxicity; CRA; cytokine release assay; CRS; cytokine release syndrome; DLT; dose limiting toxicity; EMA; European Medicines Agency; FIH; first-in-human; HHD; highest human
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Keywords: سندرم آزاد سازی سیتوکین; acute lymphoblastic leukemia; adoptive cellular therapy; CAR T cells; chimeric antigen receptors; cytokine release syndrome;
Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Keywords: سندرم آزاد سازی سیتوکین; Chimeric antigen receptor; Cytokine release syndrome; Cancer; Adverse event; Safety;
Advances in T-cell therapy for ALL
Keywords: سندرم آزاد سازی سیتوکین; acute lymphocytic leukemia; ALL; chronic lymphocytic leukemia; CLL; cytokine release syndrome; macrophage activation syndrome; chimeric antigen receptor; IL-6
A humanised mouse model of cytokine release: Comparison of CD3-specific antibody fragments
Keywords: سندرم آزاد سازی سیتوکین; SCID; severe combined immunodeficient; DFM; diFabâ² maleimide; CRS; cytokine release syndrome; PL; peritoneal lavage; TT; tetanus toxoid; IC; isotype control; IU; international units; NOD; non-obese diabetic; OKT3; SCID mouse; Human PBMC; Cytokine releas
Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy
Keywords: سندرم آزاد سازی سیتوکین; ELISA; enzyme-linked immunosorbent assay; mAbs; monoclonal antibodies; PBMCs; peripheral blood mononuclear cells; TNF; tumour necrosis factor-α; IL-6; interleukin-6; PHA; phytohaemagglutinin; VEGF; vascular endothelial growth factor; TMB; 3,3â²,5,5â²-T